文献速递呼吸道感染呼吸危重症与机械通气

右美托咪定对感染性休克患者死亡率的影响:一项随机对照试验

Dexmedetomidine for Reducing Mortality in Patients With Septic Shock: A Randomized Controlled Trial (DecatSepsis).
PubMed 文献 · Chest · 2024-07-14

该开放标签随机对照试验在90例感染性休克且心率>90次/分的患者中,评估心率校准的右美托咪定输注对院内死亡率的影响。研究不足以检测死亡率降低,但右美托咪定可能减少肾上腺素补救、持续性房颤、APACHE II评分和CRP。

要点

  • 右美托咪定可降低感染性休克患者前3天平均心率11.2次/分。
  • 院内死亡风险比0.68无统计学意义,研究把握度不足。
  • 右美托咪定减少肾上腺素补救和持续性房颤风险。

核心结论

  • 研究不足以检测右美托咪定降低感染性休克患者院内死亡率或去甲肾上腺素等效剂量。
  • 右美托咪定可能减少肾上腺素补救输注、持续性房颤、APACHE II评分和CRP。

研究设计与样本

  • 开放标签随机对照试验,纳入90例感染性休克且心率>90次/分的成人患者,无论是否接受机械通气。
  • 右美托咪定输注48小时维持心率60-90次/分,机械通气患者两组均接受常规镇静。

临床怎么用

  • 对感染性休克且心率>90次/分的患者,可考虑右美托咪定输注48小时以控制心率。
  • 右美托咪定可能有助于减少肾上腺素补救和持续性房颤,但需注意研究把握度不足。

局限性

  • 研究把握度不足,无法检测院内死亡率或去甲肾上腺素等效剂量的降低。
  • 开放标签设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sepsis, especially septic shock, and its complications have been linked to the hyperadrenergic stress response. RESEARCH QUESTION: Does decatecholaminization with dexmedetomidine lower the in-hospital mortality in patients with septic shock? STUDY DESIGN AND METHODS: This open-label randomized controlled trial assessed the effects of a heart rate (HR)-calibrated dexmedetomidine infusion on in-hospital mortality in patients with septic shock and HR of > 90 beats/min, regardless of whether they are receiving mechanical ventilation. Dexmedetomidine was infused for 48 h to maintain the HR at 60 to 90 beats/min. Mechanically ventilated patients received conventional sedation in both groups. Other outcomes were the norepinephrine equivalent dose, the need for additional vasopressor, Acute Physiology and Chronic Health Evaluation (APACHE) II score, persistent atrial fibrillation (AF), and C-reactive protein (CRP) level. RESULTS: In 90 patients of either sex, dexmedetomidine reduced the mean HR over the first 3 days in the ICU by 11.2 beats/min (95% CI, -17 to -5 beats/min; P < .001). The in-hospital mortality risk ratio (RR) was 0.68 (95% CI, 0.43-1.07; P = .091). The dexmedetomidine group received a norepinephrine equivalent dose of 0.55 μm/kg/min (interquartile range [IQR], 0.37-0.82 μm/kg/min) vs 0.61 μm/kg/min (IQR, 0.47-0.89 μm/kg/min; P = .121). Dexmedetomidine reduced the epinephrine infusion rescue (relative risk reduction, 0.6; 95% CI, 0.06-0.93; P = .025). The RR of persistent AF was 0.47 (95% CI, 0.21-0.99; P = .05). Dexmedetomidine reduced the median APACHE II score on the third day by -6 (95% CI, -10 to -2; P = .003) and the mean CRP concentration by -40 mg/dL (95% CI, -78 to -3.4 mg/dL; P = .033). INTERPRETATION: The study was underpowered to detect a reduction in in-hospital mortality or norepinephrine equivalent dose in patients with septic shock with dexmedetomidine. However, dexmedetomidine may reduce epinephrine infusion rescue, persistent AF, APACHE II score, and CRP. CLINICAL TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT05283083; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Ezz Al-Regal AR, Ramzy EA, Atia AAA, et al. Dexmedetomidine for Reducing Mortality in Patients With Septic Shock: A Randomized Controlled Trial (DecatSepsis). Chest. 2024. PMID: 39004217. doi:10.1016/j.chest.2024.06.3794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。